van Muijen Marloes E, Atalay S, van Vugt L J, Vandermaesen L M D, van den Reek J M P A, de Jong E M G J
Department of Dermatology, Radboud University Medical Centre (Radboudumc), Mailbox, 9101, 6500 HB, Nijmegen, The Netherlands.
Radboud Institute for Health Sciences (RIHS), Radboud University Medical Centre (Radboudumc), Nijmegen, The Netherlands.
Drugs Real World Outcomes. 2021 Jun;8(2):163-172. doi: 10.1007/s40801-021-00227-w. Epub 2021 Mar 28.
Personal treatment goals have been systematically investigated in psoriasis patients with active but not in controlled disease.
To explore patient needs in psoriasis patients with controlled disease due to biologic therapy with adalimumab, etanercept or ustekinumab.
Treatment needs in patients on adalimumab, etanercept or ustekinumab with a stable low disease activity for ≥ 6 months and preferably a Psoriasis Area and Severity Index (PASI) < 5, were explored with the Patient Needs Questionnaire (PNQ). Goal importance was expressed as overall mean importance score, percentage of patients that reported a goal to be quite/very important, and per PNQ subscale. Data were analysed separately for treatment, gender, age group (< 50 vs. ≥ 50 years), biologic naivety and willingness to participate in a pragmatic dose-reduction strategy.
Sixty-five patients were included. 'To be free of itching', 'to be healed of all skin defects' and 'to have confidence in the therapy' were rated quite/very important in 78.5% of the patients, followed by 'to have no fear the disease will progress' (75.4%) and 'to get better skin quickly' (75.4%). Goals related to the subscale 'confidence in healing' were still of high importance in controlled disease. Least importance was attributed towards social goals. For female patients, it was significantly more important than for males to 'feel less depressed' and 'be comfortable showing yourself more in public'.
Psoriasis patients with controlled disease still report substantial treatment needs, with high importance ascribed to confidence in healing. To apply personalized medicine, treatment needs should be explored on an individual level.
已对活动性银屑病患者的个人治疗目标进行了系统研究，但未对病情得到控制的患者进行研究。
探讨因使用阿达木单抗、依那西普或乌司奴单抗进行生物治疗而病情得到控制的银屑病患者的需求。
使用患者需求问卷（PNQ）对接受阿达木单抗、依那西普或乌司奴单抗治疗且疾病活动度稳定低水平≥6个月且银屑病面积和严重程度指数（PASI） preferably <5的患者的治疗需求进行了探讨。目标重要性用总体平均重要性评分、报告目标为相当/非常重要的患者百分比以及每个PNQ子量表来表示。分别对治疗、性别、年龄组（<50岁与≥50岁）、生物制剂初治情况以及参与务实剂量减少策略的意愿进行了数据分析。
纳入了65名患者。“无瘙痒”、“所有皮肤缺陷愈合”和“对治疗有信心”在78.5%的患者中被评为相当/非常重要，其次是“不用担心疾病进展”（75.4%）和“皮肤快速好转”（75.4%）。与“愈合信心”子量表相关的目标在病情得到控制的情况下仍然非常重要。社会目标的重要性最低。对于女性患者，“感觉不那么沮丧”和“在公共场合更自在地展示自己”比男性患者明显更重要。
病情得到控制的银屑病患者仍报告有大量治疗需求，对愈合信心高度重视。为了应用个性化医疗，应在个体层面探索治疗需求。
